Umecrine Mood AB has several compounds that in pre-clinical models of PMDD have shown inhibition of allopregnanolone-induced effect on the GABAA receptor. Importantly, these compounds have no influence on the effects of other GABAA receptor active substances including GABA itself, and consequently the inhibiting effect is specific. This points to the fact that the compounds are possible to use as pharmaceuticals to prevent the emergence of symptoms of PMDD/PMS with low risk of severe side-effects.
The selected lead product is a first-in-class compound and a GABAA modulating steroid antagonist (GAMSA). In addition to its effect demonstrated preclinically, recent clinical results also demonstrate a inhibition of allopregnanolone-induced effects on a biomarker of PMDD in women. The results support the possible therapeutic effect of the CD, and a phase II study is now planned for the demonstration of proof-of-concept.